Boy with Bike)

Our Patients

Our Promise to Patients: You Come First

Welcome home

You've likely had a long journey, but now you're among friends. We understand rare and serious conditions because we've specialized in it for decades and we're here to help. By working closely with people like Logan and his family (pictured above), we're able to identify and pursue new innovations that address unmet medical needs. Meanwhile, we continue to enhance our current treatments for conditions, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, hereditary angioedema, and Alpha-1 antitrypsin deficiency.   

We are driven by our promise to save lives and improve the quality of life for our patients and their families, because living with a rare disease impacts more than just one person. We offer support programs and activities and we partner with patient advocacy organizations to improve and expand educational and outreach efforts. We also work with government authorities to ensure patients have access to the medicines they need to live life to the fullest.

How can we help you?

Immunodefiency & Autoimmune Diseases

We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Treatments are available for the following conditions:

Hereditary Bleeding Disorders

We are a world leader in innovative medicines for the treatment of bleeding disorders. We offer the largest portfolio for the treatment of hereditary bleeding disorders with more than a dozen plasma-derived and recombinant coagulation factor concentrates. Treatments are available for the following conditions:

Hereditary Angioedema (HAE)

We recently introduced the world's first subcutaneous preventative treatment for attacks of Hereditary Angioedema (HAE), while still offering our intravenous C1-esterase inhibitor therapy for on-demand treatment.

Alpha 1 Antitrypsin Deficiency

Our Alpha 1 proteinase inhibitor treats Alpha 1 Antitrypsin Deficiency (AATD) in patients with Alpha 1-related emphysema.

Machelle Pecoraro HAE Machelle Pecoraro HAE

" Never give up and never give in. You can overcome this and find a way to do all you ever dreamt possible. "

- HAE Patient Machelle Pecoraro

Current Clinical Trials

Therapeutic Area Condition Description
Bleeding Disorders
Hemophilia A An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Hemophilia B A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Hemophilia A & B A Study to Investigate the Pharmacokinetics, Efficacy, and Safety of rVIIa-FP (CSL 689) in Subjects With Hemophilia (A or B) and Inhibitors Learn More
Congenital Fibrinogen Deficiency An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
Von Willebrand Study of Voncento® in Subjects With Von Willebrand Disease Completed
Warfarin Reversal An Observational Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA® Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding Learn More
Cardiovascular Acute Coronary Syndrome  Study to investigate CSL112 in Subjects With Acute Coronary Syndrome Learn More
  Coronary Heart Disease Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Learn More
Immunoglobulins Chronic Inflammatory Demyelinating Polyneuropathy Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Learn More
  Hereditary Angioedema (HAE) A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema Learn More 
  Pediatric CIDP Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Learn More 
  Primary Immune Deficiency (PID) Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) Learn More
Primary Immune Deficiency (PID) Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Completed
  Primary Immune Deficiency (PID) Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump  Learn More
Therapeutic Proteins Other Inflammatory or immune system disorders Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Learn More
Transplant Antibody-mediated kidney transplant rejection Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients Learn More

Participate in a Clinical Trial

Discover what is involved in participating in one of our clinical trials and how you can enroll.

Learn More

Get our latest Vita stories in your inbox
First name
Last name


You have now been added
to the CSL Behring Vita list